The coronavirus vaccine, created by pharmaceutical company AstraZeneca in collaboration with the University of Oxford, has shown low efficacy against the "South African" strain of COVID-19, The Financial Times reports under a study.
It turned out that AstraZeneca's drug could not protect vaccinated against mild and moderate forms of the disease caused by a new mutation of the coronavirus.
Simultaneously, this vaccine's effectiveness against a severe form of the disease and its effect on mortality when infected with the "South African" strain has not yet been studied.
In turn, the AstraZeneca company noted that the study was selective in nature, had a small scale, and its participants were mostly young, healthy people.
It cannot correctly indicate the effectiveness of the vaccine against the South African strain.
Notably, the "South African" strain of coronavirus 501Y.V2 was first identified in South Africa last December.